

Do I Really Need To File? HSR Avoidance and the Edwards/Genesis Settlement

A photograph of a modern building with a curved, glass-and-steel facade, viewed from a low angle looking up.

PODCAST | 1 MIN READ

August 24, 2026


For nearly 50 years, the Hart-Scott-Rodino Act has given antitrust enforcers a chance to review deals above a certain value before they can close. What happens when the government concludes a transaction was structured intentionally to slip past that review entirely?

Managing partner [Jeny Maier](#) and Lexi Michaud of Fried Frank speak with Evan Miller of Vinson & Elkins about HSR Act avoidance and the FTC's record-setting \$12 million settlement with Edwards Lifesciences and Genesis MedTech over Edwards Lifesciences's acquisition of JC Medical from Genesis. They discuss how the JC Medical deal was valued and structured, how the parties' failure to file played a role in the FTC's separate challenge to Edwards's contemporaneous JenaValve acquisition, what deal teams should consider when assessing a transaction close to the HSR threshold, what the settlement signals about the FTC's current approach to premerger notification enforcement, and more.

Watch below or on the [Our Curious Amalgam](#) website.


#392 Do I Really Need To File? HSR Avoidance and the Edwards/Genesis Settlement

ABA Antitrust Law Section



Watch on  YouTube

Related People



Jeny M. Maier

Related Services

Antitrust

To subscribe to our publications, [click here](#).

Featured Insights

- CCWC 22nd Annual Career Strategies Conference
SPONSORSHIP
- Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop

SPONSORSHIP ANTITRUST

- Women, Influence, & Power in Law Conference 2026

SPONSORSHIP ANTITRUST

- IP Litigation North America Summit 2026

SPONSORSHIP INTELLECTUAL PROPERTY

- HNBA/VIA Annual Convention 2026

SPONSORSHIP ANTITRUST

- 30th Annual IBA Competition Conference

SPEAKING ENGAGEMENT ANTITRUST

- ABA 2026 Antitrust Global Seminar Series

SPEAKING ENGAGEMENT ANTITRUST

- Axinn Attorneys Earn Top Honors in Best Lawyers 2027

NEWS ANTITRUST

- DOJ's Antitrust Division Remains Interested in Your Private Litigation

BYLINE ARTICLES ANTITRUST

- Axinn Advises Thermo Fisher Scientific on Completed \$1.075 Billion Sale of Microbiology Business to Astorg

DEALS & CASES ANTITRUST